The company, headquartered in Belgium, specializes in ultra-fast PCR-based testing designed to expedite the production of complex immunotherapies, such as CAR-T cancer treatments. By reducing sterility testing times from several days to under two hours, miDiagnostics allows pharmaceutical manufacturers to meet rigorous safety standards without sacrificing the speed required for aggressive patient care. This technical capability has become increasingly vital as personalized medicine transitions from research labs to mainstream clinical application.

Since taking the helm in 2021, Verleysen has guided the transition of miDiagnostics from a research-focused entity into a commercially scaled medtech player. A chemist by training, she has prioritized the development of infrastructure that facilitates partnerships with global pharmaceutical leaders. Her leadership has centered on the integration of scientific precision with the operational demands of international life sciences manufacturing. The firm’s current trajectory includes expanding its rapid testing technology into broader areas of immunotherapy, addressing autoimmune conditions and other complex pathologies where timing remains a critical factor in patient outcomes.